A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

This is a single-center, non-randomized, phase 2 study in which patients will receive daratumumab (subcutaneous, SC) in combination with clarithromycin/pomalidomide/dexamethasone (D-ClaPd) until progressive disease (PD) or unacceptable toxicity. This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of clarithromycin/pomalidomide/dexamethasone with daratumumab SC (D-ClaPd) will yield higher Very Good Partial Response (VGPR) rates in relapsed/refractory multiple myeloma patients than historical pomalidomide/dexamethasone treatment.

Study Overview

• Status: Active, not recruiting
• Conditions: Multiple Myeloma; Refractory Multiple Myeloma; Relapse Multiple Myeloma
• Intervention / Treatment: Drug: Clarithromycin; Drug: Pomalidomide; Drug: Daratumumab SC; Drug: Dexamethasone

• Study Type: Interventional
• Enrollment (Actual): 11
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • New York
    • New York, New York, United States, 10065
      • Weill Cornell Medicine - Multiple Myeloma Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 71 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Histologically confirmed Multiple Myeloma
• Relapsed and/or refractory myeloma defined as follows: Relapse or progressive disease after at least one previous line of therapy which must include prior daratumumab. At least 8 doses of daratumumab in a previous line must be administered either as monotherapy or in combination with a daratumumab-free interval of ≥3 months AND patient may be daratumumab refractory defined as less than a partial remission (PR) achieved on prior daratumumab-based therapy or have exhibited progression within 60 days of receiving daratumumab. If previous therapy was autologous stem cell transplant (SCT), over 3 months must have elapsed after SCT.
• Measurable disease as defined by > 0.5 g/dL serum monoclonal protein, >0.1 g/dL serum free light chains, >0.2 g/24 hrs urinary M-protein excretion, and/or measurable plasmacytoma(s).
• Females of childbearing potential(FCBP) must have a negative serum or urine pregnancy test within 10 - 14 days prior to and again within 24 hours of prescribing pomalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks before she starts taking pomalidomide. FCBP must also agree to ongoing pregnancy testing.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
• Able to take aspirin daily
• Life expectancy must be greater than 3 months.
• Be able to voluntarily sign and understand written informed consent.
• Absolute neutrophil count (ANC) ≥750 cells/mm3 (.75 x 109/L)
• Platelets count ≥ 50,000/mm3 (50 x 109/L)
• Serum SGOT/AST ≤ 2.0 x upper limits of normal
• Serum SGPT/ALT <3.0 x upper limits of normal
• Serum creatinine ≤ 2.5 x upper limits of normal
• Serum total bilirubin ≤ 1.5 x upper limits of normal (Total bilirubin ≥ 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
• All participants must be registered into the mandatory POMALYST REMS™ program and be willing and able to comply with the requirements of the POMALYST REMS™ program.

Exclusion Criteria:

• Prior exposure to non-daratumumab anti-CD38 monoclonal antibodies or pomalidomide. Prior pomalidomide exposure in 1 or more previous lines of therapy allowed if partial remission (PR) or better achieved. No disease progression may have occurred within 60 days of receiving pomalidomide.
• New York Heart Association (NYHA) Class III or IV heart failure, unstable cardiac arrhythmia, or unstable angina
• Myocardial infarction within the past 6 months
• Severe obstructive airway disease
• Planned high-dose chemotherapy and autologous stem cell transplantation within 6, 28-day treatment cycles after starting on treatment
• Female patients who are lactating or have a positive serum pregnancy test during the screening period
• Failure to have fully recovered (ie, ≤ Grade 1 toxicity) from the reversible effects of prior chemotherapy
• Major surgery within 14 days before enrollment
• Radiotherapy within 14 days before enrollment (if area involved is small than within 7 days)
• Systemic treatment, within 14 days before the first dose, with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort
• Seropositive for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C
• Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol
• Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
• Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
• Patient has greater than Grade 3 peripheral neuropathy, or Grade 2 pain
• Participation in other clinical trials within 30 days
• History of thromboembolic event within the past 6 months prior to enrollment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: daratumumab/clarithromycin/pomalidomide/dexamethasone; Induction Phase: 8 cycles (cycle length of 28 days); Daratumumab SC:1800mg SC weekly for 8 weeks for Cycle 1 and 2 1800mg SC every 2 weeks on Day 1 and 15 for Cycle 3-6 1800mg SC every 4 weeks on Day 1 for Cycle 7-8; Clarithromycin500mg PO BID until VGPR or 8 cycles, whichever occurs first; Pomalidomide 4mg PO on Days 1-21; Dexamethasone 20mg IV as pre-medication on Day 1, 8 40mg PO on the day after daratumumab for Cycle 1 Days 15 and 22 40mg PO pre-daratumumab weekly for Cycle 2-6 20mg PO pre-daratumumab weekly for Cycle 7-8 Maintenance Phase (Cycle 9+): Up to 24 cycles (cycle length of 28 days); Daratumumab 1800 mg SC on Day 1; Pomalidomide 4mg PO on Day 1-21; Dexamethasone 20mg PO pre-daratumumab weekly for Cycles 9 and beyond

Drug: Clarithromycin; Given as 500mg oral capsule; Drug: Pomalidomide; Given as 4mg oral capsule; Drug: Daratumumab SC; Given as 1800mg via injection; Other Names: Faspro; Drug: Dexamethasone; Given as 20mg IV and 20mg or 40mg oral tablets

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Very Good Partial Response Rate or Better Within 8 Cycles of Induction Therapy	Very Good Partial Response or better defined as the number of participants with a documented Very Good Partial Response (VGPR) or better as best response per International Myeloma Working Group (IMWG) criteria, measured from date of enrollment through the end of the 8th induction cycle.	up to end of 8th induction cycle (up to approximately 224 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-Free Survival	Progression-Free Survival (PFS) is measured in months from the date of enrollment to the date of disease progression and/or death. Median estimate is calculated using the Kaplan-Meier methodology.	Approximately 3 years
Overall Survival	Overall Survival (OS) is measured in months from the date of enrollment to the date of the participant's death. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier survival estimates.	Approximately 5 years
Time to Progression	Measured in months between the date of enrollment and the first efficacy evaluation at which the participant has met the criteria for Progressive Disease	Approximately 3 years
Time to Next Therapy	Measured in months from the date of enrollment to the start date of subsequent treatment for relapsed/refractory multiple myeloma	Approximately 3 years
Duration of Response	Duration of Response (DoR) is defined as the time between the date of initial documentation of best response to the date of first documented evidence of disease progression.	Approximately 3 years
Complete Response Rate or Better	The number of participants with a documented Complete Response (CR) or better, per International Myeloma Working Group (IMWG) criteria.	Approximately 1 year
Rate of Minimal Residual Disease (MRD) Negativity	Defined as a number of MRD negative participants	Approximately 8 months
Rate of Improvement in Response During Maintenance Therapy	Percentage of patients that achieved an improved response during maintenance compared to end of induction.	Approximately 3 years
Time to Best Response	Measured in months between the date of enrollment and the first efficacy evaluation at which the participant has met criteria for best response per International Myeloma Working Group (IMWG) criteria.	Approximately 9.5 months
Overall Response Rate	The number of participants with a documented Overall Response (Partial Response or better), per International Myeloma Working Group (IMWG) criteria.	Approximately 1 year
Very Good Partial Response (VGPR) Rate or Better	The number of participants with a documented Very Good Partial Response (VGPR) Rate or better, per International Myeloma Working Group (IMWG) criteria.	Approximately 1 year

Collaborators and Investigators

• Sponsor: Weill Medical College of Cornell University
• Collaborators: Janssen Scientific Affairs, LLC
• Investigators: Principal Investigator: Mateo Mejia Saldarriaga, MD, Weill Medical College of Cornell University

Study record dates

Study Major Dates

• Study Start (Actual): October 28, 2021
• Primary Completion (Actual): May 31, 2024
• Study Completion (Estimated): December 28, 2027

Study Registration Dates

• First Submitted: March 6, 2020
• First Submitted That Met QC Criteria: March 6, 2020
• First Posted (Actual): March 10, 2020

Study Record Updates

• Last Update Posted (Actual): May 20, 2026
• Last Update Submitted That Met QC Criteria: May 19, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Neoplasms; Immune System Diseases; Neoplasms by Histologic Type; Hematologic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Neoplasms, Plasma Cell; Hemostatic Disorders; Paraproteinemias; Blood Protein Disorders; Hemorrhagic Disorders; Hemic and Lymphatic Diseases; Multiple Myeloma; Organic Chemicals; Polycyclic Compounds; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Steroids, Fluorinated; Macrolides; Lactones; Pregnadienetriols; Erythromycin; Polyketides; Dexamethasone; Clarithromycin; pomalidomide
• Other Study ID Numbers: 19-12021155

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No